SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Also with regard to drugs, our study supports that glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors may be attractive therapeutic options for patients with NAFLD and HF.